But safer sourcing wont matter if it encourages people to forgo proven medical treatments for conditions like ulcerative colitis, where delaying effective therapy can increase the risk for serious complications
The IPO proceeds include ~$150M earmarked to support these oral ribupatide trials and bring them to completion ( [36] )
In its freeze-dried state, it's neatly folded and protected
We're no longer talking about "weight loss drugs." We're talking about treatments that simultaneously address visceral fat, liver fat, glycemic control, cardiovascular risk, sleep apnea, and joint disease
The program, which began in 2023, has enrolled more than 5,800 participants with additional results anticipated over the next year